Legend Biotech (LEGN) Misses Q4 EPS by 6c

Legend Biotech (NASDAQ: LEGN) reported Q4 EPS of ($0.40), $0.06 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $79.46 million versus the consensus estimate of $94.07 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• CLSA Upgrades Kao Corp. (4452:JP) (KAOOY) to Outperform (2)